Figure 3

Kaplan Meier estimate showing the relapse-free survival of MCD/FSGS patients treated with RTX. There was no difference in relapse-free survival between first, second or third/subsequent courses (p = 0.15). Median relapse-free survival is 17 months for the first application, 51 for the second course and 21 months for subsequent courses.